Ferring takes option on TxCell's IBD cell therapy
This article was originally published in Clinica
Privately-held French biotech TxCell and Ferring of Switzerland have signed a collaboration agreement potentially worth up to €76m ($105.7m) plus royalties for TxCell's lead product Ovasave for the treatment of inflammatory bowel disease (IBD).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.